Search clinical trials for: collect plasma samples and clinical features

Total 766 results

Mayo Clinic

Recruiting

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Pancreatic Carcinoma | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant... and other conditions

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Informing Oral Nicotine Pouch Regulations to Promote Public Health

Tobacco-Related Carcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Human Papillomavirus-Related Carcinoma

United States, Austria
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

Breast Carcinoma | Breast Fibrocystic Change | Benign Breast Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Dedifferentiated Chondrosarcoma | Central Chondrosarcoma, Grade 2 | Central Chondrosarcoma, Grade 3 | Metastatic Clear Cell Sarcoma of Soft Tissue | Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified

United States
National Cancer Institute (NCI)

Active, not recruiting

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

Colorectal Adenoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (AMBASSADOR)

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Ureter Cancer AJCC v7 | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Ureter Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Localized Renal Pelvis and Ureter Urothelial Carcinoma | Stage II Bladder... and other conditions

United States, Guam
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
Roswell Park Cancer Institute

Not yet recruiting

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

Malignant Solid Neoplasm

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
Timothy Voorhees

Active, not recruiting

Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study

Colon Adenocarcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8

United States
Mayo Clinic

Recruiting

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia

United States
Roswell Park Cancer Institute

Not yet recruiting

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma | Refractory Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Lynch Syndrome

United States, Puerto Rico
Emory University
National Cancer Institute (NCI); Xencor, Inc.

Recruiting

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial

Stage IV Renal Cell Cancer AJCC v8 | Metastatic Papillary Renal Cell Carcinoma

United States
Carolina Eyecare Physicians, LLC
Science in Vision; Imprimis Pharmaceuticals, Inc.

Completed

Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen

Cataract

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myelodysplastic Syndrome | Clonal Cytopenia of Undetermined Significance

United States
Mayo Clinic

Recruiting

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Human Papillomavirus-Related Carcinoma | Locally Advanced Oropharyngeal Carcinoma

United States
Children's Oncology Group

Recruiting

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors

Central Nervous System Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage 0 Breast Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Clinical Stage... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Malignant Solid Neoplasm | Adrenal Gland Pheochromocytoma | Paraganglioma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Bile Duct Adenocarcinoma | Fanconi Anemia Complementation Group Gene Mutation | Metastatic Bile Duct Carcinoma | PTEN Gene Deletion

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain

United States
National Cancer Institute (NCI)

Not yet recruiting

Studying TAK-243 in Patients With Advanced Cancer

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
Dwight Owen
National Cancer Institute (NCI)

Recruiting

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditions

United States
Mayo Clinic

Recruiting

Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Adenoid Cystic Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Melanoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

High-Risk Neuroblastoma | Patient With Insufficient Response Chemoimmunotherapy

France, Germany, Israel, Spain, United Kingdom, Belgium, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Denmark, Greece, Lithuania, Slovakia
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
Thomas Jefferson University

Recruiting

An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma

United States
University of Michigan Rogel Cancer Center

Recruiting

Gilteritinib for the Treatment of ALK NSCLC

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Northwestern University
National Cancer Institute (NCI); Moleculin Biotech, Inc.

Recruiting

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-Wildtype

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States, Canada

Search clinical trials for: collect plasma samples and clinical features

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations